Treatment of ARVC in Patients Who Survived a Cardiac Arrest or Recovered from a Haemodynamically Unstable Ventricular Arrhythmia
Clinical Scenario
This protocol covers arrhythmogenic right ventricular cardiomyopathy (ARVC) in patients who have survived a cardiac arrest, recovered from a ventricular arrhythmia causing haemodynamic instability, or experienced haemodynamically tolerated ventricular tachycardia.
These presentations represent the highest-risk end of the ARVC clinical spectrum and require structured, evidence-guided management.
High-Risk Features Used in Decision-Making
The following features are recognised as high-risk and inform individualised management decisions in patients with ARVC:
Arrhythmic syncope
NSVT
RVEF <40%
LVEF <45%
SMVT at PES
Management Approach
The structured regimen for this population includes an implantable device intervention targeting sudden death prevention. The full protocol — with specific indications, risk-tier criteria, and the complete clinical pathway — is available via the link below.
References
DOI: 10.1093/eurheartj/ehad194
- An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients with ARVC who have survived a cardiac arrest or have recovered from a ventricular arrhythmia causing haemodynamic instability.
- An ICD should be considered in ARVC patients who have suffered a haemodynamically tolerated VT.
- High-risk features should be considered to aid individualized decision-making for ICD implantation in patients with ARVC.
- High-risk features: arrhythmic syncope, NSVT, RVEF <40%, LVEF <45%, SMVT at PES.
View source ↗